Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
Discover how base editing via CRISPR-guided cytidine deamination could revolutionize CAR T-cell therapy for T-cell cancers, offering a promising approach to treating relapsed or refractory cases in pediatric patients.
Hematology/Oncology September 11th 2023
Oncology Learning Network
Explore the findings of the A041702 study, presented at the ASCO annual meeting, which investigated the efficacy of two treatment regimens for older patients with CLL. The results, significantly influenced by COVID-19, call for further investigation and long-term follow-up to determine the potential benefits and risks.
Hematology/Oncology August 14th 2023
ReachMD
This is a golden opportunity to bolster your understanding of AML, implement novel diagnostic strategies, and integrate state-of-the-art treatment plans into your practice. Enrich your professional knowledge, earn valuable CME credits, and most importantly, help improve the lives of your patients.
Clinical Pharmacology July 25th 2023
Clinical Advances in Hematology & Oncology
Uncover the potential of nivolumab and axicabtagene ciloleucel as they showcase promising results in the latest lymphoma trials, potentially reshaping the standard of care for these malignancies.
Hematology/Oncology July 25th 2023
OBR Oncology
Explore the CML SUN study’s findings, which highlight the unmet need for shared decision-making in the choice of CML treatment—a void that may have an impact on patient satisfaction and treatment outcomes.
Dana-Farber Cancer Institute
Gain insight into how a shift in cellular environment and UV radiation exposure can instigate additional mutations, deepening our understanding of the evolution and development of rare and complex malignancies such as BPDCN.
Dermatology July 18th 2023